Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus Bevacizumab as Adjuvant Therapy in High-Risk Hepatocellular Carcinoma
NCT04102098Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2019
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Roche. Primary endpoint: Recurrence-Free Survival at 33 months. Started Dec 2019; status: completed.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04102098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04102098.